At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Modulation of the FOLFIRI-based Standard First-line Therapy With Cetuximab, Controlled by Monitoring the RAS (Rat Sarcoma) Mutation Load by Liquid Biopsy in RAS-mutated mCRC (Metastatic Colorectal Cancer): A Randomized Phase II Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab (MoLiMoR)
In Brief
A Phase 2 clinical trial evaluating Cetuximab and FOLFIRI for Adenocarcinoma of the Colon and Adenocarcinoma of the Rectum. Completed, enrolled 6 participants across 4 sites.
Detailed Summary
This is an open-label, prospective, randomized, multicenter phase II trial that will evaluate the efficacy and safety of intermittent addition of cetuximab to a FOLFIRI-based first line therapy to patients with RAS (Rat sarcoma)-mutant mCRC (Metastatic colorectal cancer) diagnosis who convert to RAS wild-type using monitoring of the RAS mutation status by liquid biopsy.
Study Details
Timeline
Interventions
Patients in Arm A will receive FOLFIRI +cetuximab.
Irinotecan, Folinic acid (racemic), Fluorouracil (5-FU)